1 Usability, acceptability and cost of the SD BIOLINE Ov16 rapid

2 diagnostic test for onchocerciasis surveillance in endemic

communities in the middle belt of Ghana

4 Kenneth Bentum Otabil^{*1,2}, María-Gloria Basáñez³, Ameyaa Elizabeth⁴, Michael Oppong⁴, Prince

5 Mensah⁴, Richmond Gyasi-Ampofo⁴, Emmanuel John Bart-Plange^{1,4}, Theophilus Nti Babae¹,

6 Lydia Datsa⁵, Andrews Agyapong Boakye⁶, Michael Tawiah Yeboah⁷, Prince Nyarko¹, Prince

- 7 Charles Kudzordzi¹, Anabel Acheampong¹, Edwina Twum Blay¹, Henk D.F.H. Schallig⁸, Robert
- 8 Colebunders⁹
- ⁹ ¹Consortium for Neglected Tropical Diseases and One Health, Centre for Research in Applied
- Biology, School of Sciences, University of Energy and Natural Resources, Sunyani, Bono Region,
 Ghana
- ²Department of Biological Science, School of Sciences, University of Energy and Natural
 Resources, Sunyani, Bono Region, Ghana
- ³Department of Infectious Disease Epidemiology, MRC Centre for Global Infectious Disease
- 15 Analysis (MRC GIDA), and London Centre for Neglected Tropical Disease Research, School of
- 16 Public Health, Imperial College London, London, UK
- ⁴Department of Medical Laboratory Science, School of Sciences, University of Energy and
- 18 Natural Resources, Sunyani, Bono Region, Ghana
- 19 ⁵Deo Gratias Medical Laboratories, Sunyani, Bono Region, Ghana
- 20 ⁶Kintampo Health Research Centre, Kintampo, Bono Region, Ghana
- ⁷Ghana Health Service, Regional Neglected Tropical Diseases (RNTD) Office, Regional Health
- 22 Directorate, Sunyani, Bono Region, Ghana
- 23 ⁸Academic Medical Centre, Department of Medical Microbiology, Experimental Parasitology
- 24 Unit, Amsterdam University Medical Centres Amsterdam, The Netherlands
- ⁹Global Health Institute, Faculty of Medicine and Health Sciences, University of Antwerp,
- 26 Belgium
- 27 ***Corresponding Author: Email:** <u>kenneth.otabil@uenr.edu.gh</u> Tel: +233209164671
- 28
- 29 Short Title: Ov16 rapid diagnostic test for onchocerciasis surveillance in Ghana
- 30

31 Abstract

32 Background

Previous studies in the Bono Region (middle belt) of Ghana have reported persistent *Onchocerca volvulus* infection and associated morbidities after nearly three decades of ivermectin treatment. This study aimed to assess the usability, acceptability and cost of the Ov16 SD BIOLINE rapid diagnostic test (Ov16 RDT) in onchocerciasis surveillance activities in the middle belt of Ghana.

38 Methodology

A cross-sectional study was conducted in 6 endemic communities in the Tain District and Wenchi Municipality. A total of 254 individuals (54% females; median age (range)=31 (5–83) years), agreed to participate in Ov16 RDT (100%), skin-snip microscopy (37%) and nodule palpation (100%). Post-test interviews were conducted for all 94 participants tested by all three diagnostics. A cost analysis based on testing 400 people was performed.

44 **Principal findings**

45 Ov16 seroprevalence was 23.6% (60/254, 95%CI=18.8%–29.2%); microfilarial prevalence 11.7% 46 (11/94, 95%C) = 6.7%-19.8%) and nodule prevalence 5.5% (14/254, 95%C) = 3.3%-9.0%). The proportion of Ov16 seropositive females (43/136, 31.6%) was twice that of males (17/117, 47 14.5%). Among 5–9-year-olds, Ov16 seroprevalence was 11.1% (3/27), microfilarial prevalence 48 23.1% (3/13) and nodule prevalence 3.7% (1/27). For the 94 participants with all three tests, 49 there was no association between the results of Ov16 RDT, skin-snip microscopy and/or nodule 50 palpation. Most participants and technicians preferred Ov16 RDT because of being less painful 51 52 and invasive, easier to use and faster. Had 400 participants been tested, the total cost per 53 individual would be US\$24 (Ov16 RDT) and US\$74 (skin-snip microscopy).

54 Conclusions

55 Ov16 RDT is more acceptable and affordable (a third of the cost) compared to skin-snipping for 56 surveillance activities in transmission hotspots in Ghana.

- 57 Keywords: Onchocerciasis, Ov16 seroprevalence, microfilaridermia, nodule palpation,
- 58 ivermectin, Ghana

59 Author summary

Onchocerciasis (River blindness) is a neglected tropical disease targeted by the World Health 60 Organization for elimination of transmission in 12 endemic countries by 2030. There is a need 61 for field-friendly, acceptable and affordable tools to monitor progress towards elimination. In 62 Ghana, the SD BIOLINE Ov16 rapid diagnostic test (Ov16 RDT) has been used in several 63 epidemiological surveys, but its usability, acceptability and cost have not been assessed. We 64 studied 6 endemic communities with persistent infection after nearly three decades of 65 ivermectin treatment. The prevalence of seropositivity by Ov16 RDT was twice the prevalence 66 of skin-snip microscopy positivity and four times the prevalence of nodule-palpation positivity. 67 For the individuals tested by all three diagnostics, we found no agreement between the results 68 of Ov16 RDT and skin-snip microscopy (and/or nodule palpation), likely owing to the long-term 69 treatment in the study area. The Ov 16 RDT was acceptable to both study participants and 70 technicians because it was less painful and invasive, and yielded results more quickly. The cost 71 72 of skin-snip microscopy would be thrice that of Ov16 RDT when testing 400 individuals. Ov16 RDT is more acceptable and less costly than skin-snipping for surveillance activities in 73 74 transmission hotspots in Ghana.

75

76 Introduction

Onchocerciasis is a severely debilitating, vector-borne neglected tropical disease (NTD) caused 77 by infection with the filarial nematode Onchocerca volvulus and transmitted among humans by 78 the bites of Simulium blackflies. Although the great majority (99%) of the cases are found in 79 80 sub-Saharan Africa (SSA), the infection also occurs in Yemen and in two (Venezuela and 81 Brazil).out of the six original endemic countries in Latin America [1]. In 2017, it was estimated that at least 220 million people required preventive chemotherapy against onchocerciasis, and 82 according to the Global Burden of Disease (GBD) Study for that year, 14.6 million of those 83 84 infected had skin disease and 1.15 million had vision loss [2]. In 2019, the GBD Study estimated 85 that 19.1 (95% Uncertainty Interval, UI = 17.2-20.9) million people were infected, and that the 86 disease was responsible for 1.23 (95%UI = 0.765-1.82) million disability-adjusted life-years 87 (DALYs) [3]. Preventive chemotherapy relies on mass drug administration (MDA) delivered, in Africa, as community-directed treatment with ivermectin (CDTI), predominantly annually, but in 88 several foci of some countries (such as Ethiopia, Ghana, Nigeria, Togo and Uganda), also 6-89 90 monthly (biannually). Ivermectin is mainly microfilaricidal, and therefore CDTI programmes are 91 typically prolonged, partly due to the long lifespan of adult O. volvulus [4]. Elimination 92 (interruption) of transmission (EOT) has been reported for some foci of Mali, Senegal, Nigeria and Sudan, without vector control [5]. 93

In consequence, the World Health Organization (WHO) 2021–2030 NTD roadmap has proposed
that 12 endemic countries be verified for EOT of onchocerciasis by 2030 [6]. The WHO has
delineated three distinct phases in onchocerciasis elimination programmes: I) the treatment
phase with CDTI, during which monitoring and evaluation are conducted periodically to

ascertain progress towards transmission suppression and ultimately interruption; II) the post-98 99 treatment surveillance (PTS) phase, during which CDTI is no longer delivered but indicators of 100 exposure and transmission are evaluated to confirm that EOT has been reached, and III) the post-elimination surveillance (PES) phase, to alert of potential resurgence of transmission or re-101 102 introduction of infection [7]. These distinct phases require different diagnostic tools that allow transitioning from one to the next. During phase I, and until Stop-MDA surveys are conducted, 103 104 the gold standard for parasitological diagnosis and calculation of epidemiological indicators 105 (microfilarial prevalence and load), has been the detection and enumeration of O. volvulus 106 microfilariae by the so-called skin-snip microscopy method [8]. Skin-snip microscopy is highly 107 specific provided that microfilarial morphometric characteristics are assessed, and able to detect active infection (as microfilariae are the embryonic progeny of reproductively active 108 109 adult worms), but its sensitivity (based on two snips) decreases as microfilarial prevalence and 110 load declines due to CDTI [9]. The procedure is also mildly invasive and resource-intensive, and 111 its acceptability diminishes in communities where decades of skin-snipping have occurred [10].

Skin-snip Polymerase Chain Reaction (PCR) has been suggested to circumvent the problem of 112 low sensitivity posed by dwindling skin microfilarial loads, to confirm the infection status of 113 114 Ov16-seropositive children, or when species-specific identification of microfilariae may be necessary [11]. However, it is not practical for large-scale community surveillance in SSA 115 116 because it is expensive to purchase and operate and requires highly-skilled personnel. 117 Serological, enzyme-linked immunosorbent assay (ELISA) tests based on the detection and quantification of IgG antibodies to the O. volvulus Ov16 recombinant antigen have shown, in 118 longitudinal human and chimpanzee studies, that Ov16 seropositivity may precede skin-snip 119

positivity, providing a marker of exposure to early infection stages [12]. Other studies, also in 120 chimpanzees, have indicated that Ov16 (IgG4) seroconversion coincides with the onset of 121 patency (detectable skin microfilariae) [13], but as its duration may exceed that of patent 122 infection, Ov16 seropositivity may not yield a useful marker of active infection. Besides, ELISA-123 124 based serological tests also pose challenges including the need for laboratory analysis and the lack of a standardized, commercially-available Ov16 ELISA test, resulting in marked inter-125 126 laboratory variation [14]. A field-friendly, rapid diagnostic test (RDT) with the potential for integration into current onchocerciases surveillance activities in endemic countries, was 127 developed and made commercially available (SD BIOLINE Onchocerciasis IgG4 rapid test) 128 129 [14,15]. The performance of this Ov16 RDT has been evaluated in the field and current research priorities focus on operational and implementation research to demonstrate its usefulness, 130 131 particularly in communities with low infection prevalence as a result of many years of CDTI [16].

In Ghana, ivermectin MDA has been implemented for more than 30 years, having started in the 132 133 late 1980s [17]. In 2009, a nationwide rapid epidemiological mapping of onchocerciasis (REMO) evaluation was conducted to provide updated information on the distribution of the disease. 134 Areas with an infection (palpable nodule) prevalence in adult male samples above 20%, were 135 136 allocated to a biannual treatment frequency, also considering a buffer zone of 20 km around these CDTI priority areas [18]. Forty-four districts were classified as meso- and hyperendemic 137 138 and have received biannual MDA since 2010. Forty-one districts, which were re-classified as of 139 low endemicity and were already on MDA before the REMO exercise, continued to receive annual MDA. From 2015 to 2020, efforts were intensified to accelerate the shift from 140 onchocerciasis control to EOT. An operational threshold of microfilarial prevalence <1% was 141

adopted, the implementation unit changed from community to sub-district, and the 142 143 geographical and (reported) therapeutic coverage increased substantially. In 2017, an impact assessment survey was carried out using Ov16 serology in children aged <10 years and skin-snip 144 microscopy in adults aged ≥20 years [19]. Together with historical data collected by the 145 146 Onchocerciasis Control Programme in West Africa (OCP), the impact assessment helped the national NTD Programme to formulate strategies to reach EOT. Delineation epidemiological 147 surveys were conducted in 50 hypoendemic districts that had never received ivermectin (not 148 149 having been previously prioritized for control but in need of re-assessment for elimination), and treatment strategies and management decisions were redefined [18]. Currently, 137 districts 150 151 require or are under biannual CDTI [19].

Previous studies in the Bono region of Ghana, in which some communities had been under biannual CDTI since 2010, revealed that *O. volvulus* infection and associated cutaneous and ocular morbidities persisted despite 27 years of treatment [19,20], and that despite high levels of reported coverage [20], treatment adherence was relatively poor [21]. Although such communities may not be ready to move from the treatment phase to Stop-MDA surveys, or may require alternative interventions to accelerate progress [22] it is important to understand the role of different diagnostics for surveillance activities.

As Ghana transits from the treatment phase to the next stages of the EOT pathway in some endemic areas, and to evaluate progress towards suppression and interruption of transmission, the suitability of current diagnostic tools to accompany such transition needs to be ascertained. Whilst studies from other countries have investigated the acceptability, usability and cost of the

Ov16 RDT [10], no such study has been conducted in Ghana. Therefore, this study aimed to assess the feasibility of integrating Ov16 RDT into onchocerciasis surveillance activities in Ghana based on diagnostic attributes, technician and community acceptability, usability and cost.

166 Materials and methods

167 Study area

The study was performed in six communities, namely, four communities in the Tain District 168 (Abekwai 2, Abekwai 3, Attakrom and Kokomba) and two communities in the Wenchi 169 170 Municipality (Blibor and Jonnykrom/Adamakrom), in the Bono Region of Ghana. Fig 1 shows the 171 locations of the study villages. The communities were selected based on the following criteria informed by previous studies [19,20]: i) they had persistent endemicity for O. volvulus infection, 172 albeit with relatively low prevalence; ii) they had received ivermectin MDA for at least 20 years 173 and biannual CDTI for about 10, and iii) they were situated close to fast-flowing rivers (the 174 175 Subin, the Tain, or their tributaries) where the blackfly vectors breed.



177 Fig 1. Map of study communities in the Tain District and Wenchi Municipality, Bono Region,

178 **Ghana.** The light pink area to the right of the study area represents the Nkoranza North District.

179

176

180 Study design and recruitment

This was a cross-sectional study, using both quantitative and qualitative approaches. Upon entry into the communities, the research team first met the chief and opinion leaders to explain the purpose, design, and procedures of the study. Once the community leaders agreed to participate and a date for the survey was decided, announcements were made via 'gong-gong' beaters and/or information centres to request community members to gather at a specific point in the village on the day. On the set day, the study was explained to the residents, and a

total of 254 individuals aged \geq 5 years agreed to participate in some or all components of the 187 study, namely, a sociodemographic and health history questionnaire, Ov16 RDT testing (SD 188 BIOLINE Onchocerciasis IgG4 Rapid Test), two skin-snip biopsies for microscopy, nodule 189 palpation, and a post-test (exit) interview to assess their perceptions on the tests deployed and 190 191 to understand in which tests they would be willing to participate in future surveys. Participants (or their parents/guardians) were asked to sign an informed consent form. Table 1 provides 192 193 details on the numbers recruited at each community, their sex composition and median age, 194 and the numbers examined for each onchocerciasis diagnostic. The study was conducted between June and August 2021. 195

196 **Ethical considerations**

Ethical clearance for this study was obtained from the Committee for Human Research and 197 198 Ethics of the University of Energy and Natural Resources in Sunyani, Ghana, West Africa 199 (approval number: CHRE/AP/012/021). The study was explained to the parents/guardians and school-age children in the local dialect (Twi). Informed written consent for children less than 18 200 years of age was given by their parents/guardians. Children gave oral assent to confirm their 201 willingness to participate in the study. Participants were informed that they had the option of 202 withdrawing at any stage of the study, without having to give any reasons, and without any 203 consequences following withdrawal. 204

205 Sociodemographic questionnaire

Participants were asked to state their sex and age, and respond to questions regarding whether
they had been born in the village (yes or no); their duration of residence in the community (<1

year or ≥ 1 year); whether they lived close to a stream (yes or no), visited a stream (yes or no) and how often (every day or less than everyday), and their occupation (farming or nonfarming), with the aim to obtain information indicative of exposure to explore its association with Ov16 status (positive or negative).

212 **Ov16 rapid diagnostic test**

The deployment of the IgG4-based SD BIOLINE rapid diagnostic test (Ov16 RDT) followed the 213 214 manufacturer's instructions (Standard Diagnostics, Yongin-si, Gyeonggi-do, South Korea) and 215 quality-assurance procedures. Briefly, the test cassette was labelled with the participant's 216 unique identification number. A finger of the participant was selected, cleaned with an alcohol 217 swab and pricked with the lancet provided with the kit. The blood was then collected using a capillary tube and the blood was placed in the specimen well of the cassette. Four drops of 218 219 assay diluent were also placed in the assay diluent well. RDT results were read after 20 minutes 220 [10]. The product insert for the Ov16 RDT states that, compared to skin-snip microscopy as the gold standard, its sensitivity is 81.1% (95%Cl = 70.7%–88.4%) and its specificity is 99.0% (95%Cl 221 = 94.8%–99.8%) using whole blood [10]. 222

223 Skin-snip microscopy

Skin snipping was performed as described in our previous studies [19,20]. Briefly, the left and right iliac crests of each participant were disinfected using alcohol swabs. Holth corneoscleral punches were used to take about 2mg of bloodless skin snips each from the left and right iliac crests. The snips were placed separately in microtitre wells containing 100 µl normal saline (NaCl 0.85%) and incubated at room temperature for 24 hours. After this period, the incubation

229 medium was pipetted onto a microscope slide and examined using, firstly, a x10 and 230 subsequently a x40 objective lens. If microfilariae (mf) had emerged, the participant was 231 recorded as skin-snip positive.

232 Nodule palpation

All participants were examined for palpable nodules by trained members of the medical team (including a doctor, nurse and laboratory technicians) with experience in detecting onchocercal nodules (onchocercomas). Palpations were done on bony protuberances of the ribs, iliac crests, sacrum and upper leg, but not at locations (neck, axillae, inguinal) typical for lymph nodes. Nodules were defined as 'suspected' onchocercomas (i.e., not confirmed by dissection or biopsy) which were firm, often flattened or bean-shaped, usually movable, non-tender and up to several centimetres in diameter.

240 Usability and acceptability of Ov16 RDT

To assess the usability and acceptability of the RDT, all of the RDT technicians (n=9) who also 241 had experience in skin-snip microscopy, and community residents (n=94) who participated in all 242 243 three tests (RDT, skin-snip microscopy and nodule palpation) were interviewed (S1 Text). The 244 interview guide was developed along the themes of preference and reasons for preference by participants and technicians regarding the use of Ov16 RDT for surveillance following [10]. The 245 246 interviews were recorded using an audio recorder on Android phones and transcribed verbatim. Interview data were coded using content analysis based on key themes from the 247 semi-structured interviews as done in [10]. 248

249 Economic costs

250 To evaluate the cost associated with the implementation of onchocerciasis surveillance 251 programmes in Ghana using Ov16 RDT and skin-snip microscopy, a costing analysis was done 252 based on 400 participants as the basis for our calculations to enable comparison of costs for 253 each test without the effect of the numbers actually tested in any given survey. Briefly, the 254 value of volunteers' time as well as the surveillance costs were computed using the 'ingredient' 255 approach, multiplying the input prices by the number of inputs used [23]. The major input 256 prices for this analysis were the cost of each: a) Ov16 RDT (US\$2.82 per cassette); b) Holth corneoscleral punch (US\$423.5 per punch), and c) optical microscope (US\$1,694). In addition, 257 costs were captured for all activities conducted during the surveillance activity, including 258 training, fieldwork and data reporting. Fieldwork cost categories were further split into 259 260 transport and lodging, supplies, devices and instruments, and labour. An exchange rate of 261 GHS7.08 (cedis) per US\$ was used in agreement with the rate for 2021.

262 **Data analysis**

Data were entered in purposely designed MS Excel spreadsheets (one for the epidemiology 263 results and another for the cost menus). Analyses were conducted using Jamovi Desktop 264 (version 2.3.19) and GraphPad Prism 8 for macOS (version 8.2.1). Two x two contingency tables 265 for the (dichotomous) responses to the sociodemographic questionnaire and Ov16 status 266 267 (positive or negative) were analysed using (two-tailed) Chi-squared test (without Yates 268 continuity correction as all frequencies were greater than 1) [24]. Two x two tables for 269 concordance were analysed for those participants who underwent all three tests, firstly 270 comparing Ov16 with skin-snip results and secondly, comparing Ov16 with skin-snip and/or

271 nodule-palpation results combined as 'Oncho' status. For such analyses we report the values of 272 the following parameters: i) kappa statistic and its 95% confidence interval (95%CI), a measure of agreement between the results of two alternative techniques of categorical assessment that 273 274 takes into account whether the agreement is occurring by chance; ii) the overall proportion of 275 agreement (p_0) ; iii) the proportion of positive agreement (p_{pos}) ; iv) the proportion of negative 276 agreement (p_{neg}) , v) the McNemar's Chi-squared statistic with its P-value; and vi) the sensitivity. 277 specificity, positive predictive value (PPV) and negative predictive value (NPV) [25,26]. When 278 reporting proportions, 95%Cls were calculated using the Wilson score method [27]. Proportions 279 were compared by assessing their 95%Cls or by using the z-statistic where appropriate (non-280 paired data), in which case asymptotic 95%Cls are reported [24]. The significance level for all analyses was set at 0.05. A sample size was not calculated a priori for the study sites; our 281 282 sample is a convenience sample with an average sample size of 12% (range=5%-33%) of the 283 community populations (Table 1). The number of participants recruited per village (at least 30 participants per community) is consistent with the usual number of individuals per village 284 285 recruited for onchocerciasis epidemiological studies [28].

286 **Results**

Of the total of 254 individuals, there were 253 with recorded sex, consisting of 136 (53.8%) females and 117 (46.3%) males. Age was recorded for 242 individuals, with a median age of 31 (range=5–83) years (Table 1). Respectively, 254 (100%), 94 (37%) and 254 (100%) individuals agreed to participate in the Ov16 RDT, skin-snip microscopy and nodule palpation tests.

Therefore 94 participants underwent all three tests. The proportion of the population for whom microfilaridermia was assessed ranged from 26% to 47%.

Of the 254 individuals tested for Ov16 RDT, 60 (23.6%, 95%CI = 18.8 %–29.2%) were seropositive, compared to 11 (11.7%, 95%CI = 6.7%–19.8%) microfilaria-positive individuals out of the 94 with skin-snip results (z-value = 2.5; P-value = 0.0143). For palpable nodules, 14 out of 254 individuals examined were positive (5.5%, 95%CI = 3.3%–9.0%). The prevalence of palpable nodules was only marginally significantly different from that of microfilaridermia (z-value = 2, Pvalue = 0.0471), but highly significantly different from that of Ov16 (z-value = 5.8, P-value <0.0001).

300

301 Table 1. Characteristics of the population sampled for each study community in the Bono

302 region of Ghana.

Community	Recruited/	S	ex [†]	Median	No. Tested		
	Population	Females	Males	age" (range)	Ov16 RDT	Skin snip (%)	Nodules
	(%)	(%)	(%)	(Years)	(%)		(%)
		Та	ain District				
Abekwai 2	30/150	17	13	22	30	11	30
	(20.0%)	(56.7%)	(43.3%)	(5–61)	(100%)	(36.7%)	(100%)
Abekwai 3	60/700	29	31	30	60	23	60
	(8.6%)	(48.3%)	(51.7%)	(5–83)	(100%)	(38.3%)	(100%)
Attakrom	41/800	21	19^{\dagger}	47	41	15	41
	(5.1%)	(52.5%)	(47.5%)	(9–80)	(100%)	(36.6%)	(100%)
Kokomba	40/120	24	16	25	40	16	40
	(33.3%)	(60.0%)	(40.0%)	(7–60)	(100%)	(40.0%)	(100%)
		Wenc	hi Municipalit	ÿ			
Blibor	47/240	18	29	27	47	12	47
	(19.6%)	(38.3%)	(61.7%)	(7–80)	(100%)	(25.5%)	(100%)
Johnykrom/	36/170	27	9	41	36	17	36
Adamakrom	(21.2%)	(75.0%)	(25.0%)	(6–72)	(100%)	(47.2%)	(100%)
			Total		·		·
	254/2,180	136	117	31	254	94	254
	(11.7%)	(53.8%)	(46.3%)	(5–83)	(100%)	(37.0%)	(100%)

^{*}Of the 254 participants, sex was recorded for 253 (sex missing for one participant in Attakrom).
 [®]Age was recorded for 242 participants (age missing for one participant in each of Abekwai 2 and Abekwai 3, four participants in Attakrom, three in Kokomba and three in Johnykrom).
 306

The distribution of Ov16 status based on (dichotomised) sociodemographic information and 307 308 infection status is presented in Table 2. The following variables were statistically significantly associated with Ov16 status (positive or negative): sex (female or male), age (<30 or \geq 30 309 years), occupation (farming or not farming) and palpable nodules (positive or negative). 310 311 Microfilaridermia and Ov16 statuses were not associated. Among seropositives, the proportion of females (71.7%, 95%CI = 59.2%-81.5%) was statistically significantly higher than 312 313 that of males (28.3%, 95%CI = 18.5%-40.8%); the proportion of those aged ≥ 30 years (76.4%, 314 95%Cl = 63.7%-85.6%) was higher than those aged <30 (23.6%, 95%Cl = 14.4%-36.4%), and 315 the proportion of farmers (84.8%, 95%CI = 73.5%–91.8%) was higher than that of non-farmers 316 (15.3%, 95%Cl = 8.2%–26.5%). The proportion of those without microfilaridermia (89.5%, 95%Cl = 68.6%–97.1%) was higher than of those with a positive skin snip (10.5%, 95%Cl = 317 318 2.9%–31.4%), and the proportion of those without palpable nodules (88.3%, 95%Cl = 77.8%– 319 94.2%) was higher than of those presenting onchocercomas (11.7%, 95%CI = 5.8%-22.2%).

Also among the Ov16 seropositives, the proportion of those living close to streams (81,7%, 95%CI = 70.1%–89.4%) was higher than that of those who did not live close (18.3%, 95%CI = 10.6%–29.9%), and the proportion of those visiting streams (71.4%, 95%CI = 58.5%–81.6%) was higher than that of those who did not visit streams (28.6%, 95%CI = 18.4%–41.5%). However, the proportion of those visiting streams daily was lower (25.7%, 95%CI = 14.2%– 42.1%) than of those visiting less frequently (74.3%, 95%CI = 57.9%–85.8%).

The two participants who were both Ov16 and skin-snip positive were females who had taken ivermectin in the previous year (2019). Of the 17 participants who were Ov16 positive but

328 skin-snip negative, 13 (76.5%) were female and all 17 had taken ivermectin in the previous

329 year.

Table 2. Sociodemographic information, infection status and Ov16 RDT status of participants.

Description [No. participants for whom data were collected]	No. Ov16 Negative (%)	No. Ov16 Positive (%)	X ² statistic (P-value⁺)
Sex [253]			
Female	93 (36.8%)	43 (17.0%)	10.15
Male	100 (39.5%)	17 (6.7%)	(0.0014)
Age [242]			
<30 years	101 (41.7%)	13 (5.4%)	15.74
≥30 years	86 (35.5%)	42 (17.4%)	(0.0001)
Duration of stay in the village [244]			
Born in village and <1 year	92 (37.7%)	23 (9.4%)	0.57
≥1 year	98 (40.2%)	31 (12.7%)	(0.4490)
Proximity to stream [254]			
Yes	166 (65.4%)	49 (19.3%)	0.54
No	28 (11.0%)	11 (4.3%)	(0.4639)
Visit stream [236]			
Yes	133 (56.4%)	40 (16.9%)	0.13
No	47 (19.9%)	16 (6.8%)	(0.7162)
Frequency visiting stream [170]			
Everyday	47 (27.6%)	9 (5.3%)	1.04
<everyday< td=""><td>88 (51.8%)</td><td>26 (15.3%)</td><td>(0.3073)</td></everyday<>	88 (51.8%)	26 (15.3%)	(0.3073)
Occupation [251]			
Farming	127 (50.6%)	50 (19.9%)	7.51
Non-farming	65 (25.9%)	9 (3.6%)	(0.0061)

Presence of skin microfilariae [94]			
Yes	9 (9.6%)	2 (2.1%)	0.03
No	66 (70.2%)	17 (18.1%)	(0.8583)
Presence of palpable nodules [254]			
Yes	7 (2.8%)	7 (2.8%)	5.71
No	187 (73.6%)	53 (20.9%)	(0.0168)

[†]P-value for the 2-tailed Chi-squared statistic for 2 x 2 contingency tables.

332

333 Prevalence by age and sex of test positivity for Ov16 RDT, skin-snip microscopy and nodule

334 palpation

Table 3 presents the results of the age and sex distribution of Ov16 RDT, skin-snip and palpable 335 336 nodule positivity. The prevalence of the three indicators tended to be higher among those aged ≥30 years, but confidence intervals were wide. The seroprevalence in this age group was 32.8% 337 338 (95%CI = 25.3%–41.3%). In the 5–9 age group, 3/27 children (11.1%, 95%CI = 3.9%–28.1%) were 339 Ov16 positive, 3/13 children (23.1%, 95%CI = 8.2%-50.3%) skin-snip positive, and 1/27 (3.7%, 95%Cl = 0.7%–18.3%) nodule positive. The results by year of age for Ov16 were: 0/4 for 5-year-340 341 olds, 0/5 for 6-year-olds, 1 (boy)/9 for 7-year-olds, 0/3 for 8-year-olds and 2 (one boy and one 342 girl)/6 for 9-year-olds. For skin-snip positivity, the results were: 0/3 for 5-year olds, 1 (boy)/4 for 6-year olds, 2 (one boy and one girl)/3 for 7-year olds, 0/2 for 8-year olds and 0/1 and 9-year 343 344 olds. The nodule-positive child (boy) was aged 5. The prevalence of Ov16 seropositivity among 345 females (31.6%) was twice as high as that among males (14.5%), and this difference was statistically significant (z-value = 3.2, P-value = 0.0014). Fig 2 presents Ov16 seropositivity by 346 age group and sex for the 242 participants with recorded age. 347

349 *volvulus* in the study communities, Bono Region, Ghana.

Category	Positivity by Ov16 RDT	Positivity by skin-snip	Positivity by nodule palpation
	n +ve/N examined	n +ve/N examined	n +ve/N examined
	(%) [95% CI]	(%) [95% CI]	(%) [95% CI]
Age [†] (years)			
5–9	3/27 (11.1%) [3.9% – 28.1%]	3/13 (23.1%) [8.2% – 50.3%]	1/27 (3.7%) [0.7% – 18.3%]
10–19	2/36 (5.6%) [1.5% – 18.1%]	2/15 (13.3%) [3.7% – 37.9%]	2/36 (5.6 %) [1.5% – 18.1%]
20–29	8/51 (15.7%) [8.2% – 28.0%]	2/16 (12.5%) [3.5% – 36.0%]	1/51 (2.0%) [0.4% – 10.3%]
30–39	11/32 (34.4%) [20.4% – 51.7%]	3/10 (30.0%) [10.8% – 60.3%]	2/32 (6.3%) [1.7% – 20.2%]
≥40	31/96 (32.3%) [23.8% – 42.2%]	1/37 (2.7%) [0.5% – 13.8%]	8/96 (8.3%) [4.3% – 15.6%]
Total	55/242 (22.7%) [17.9% – 28.4%]	11/91 (12.1%) [6.9% – 20.4%]	14/242 (5.8%) [3.5% – 9.5%]
Sex [₽]			
Female	43/136 (31.6%) [24.4% – 39.9%]	6/53 (11.3%) [5.3% – 22.6%]	6/136 (4.4%) [2.0% – 9.3%]
Male	17/117 (14.5%) [9.3% – 22.0%]	5/41 (12.2%) [5.3% – 25.5%]	8/117 (6.8%) [3.5% – 12.9%]
Total	60/253 (23.7%) [18.9% – 29.3%]	11/94 (11.7%) [6.7% – 19.8%]	14/253 (5.5%) [3.3% – 9.1%]

^t Age was recorded for 242 of the 254 participants. ^{II} Sex was recorded for 253 participants.

351

352



353



356

357 Concordance between tests

358 Table 4 presents the results of the 2 x 2 concordance test between the Ov16 RDT assay and 359 skin-snip microscopy for the 94 participants from whom skin biopsies were taken, as well as 360 the results of Ov16 RDT compared with the 'Oncho' status of the same participants 361 (combining the results of skin-snip microscopy and nodule palpation). In both cases, the 362 value of kappa is not statistically different from zero, indicating poor agreement between 363 tests after correcting for chance agreement [26]. The McNemar's Chi-squared statistics and 364 corresponding P-values indicate that the results of the tests are not significantly associated, 365 with a proportion of positive agreement between 13% and 18%, a proportion of negative agreement of approximately 83%, and a proportion of overall agreement of roughly 70%. 366 367 The sensitivity of the Ov16 RDT was about 20% and its specificity of about 80% in 368 comparison to skin-snip microscopy or skin-snip and/or nodule palpation.

369 Table 4. Two x two concordance results for the comparison between Ov16 Rapid

370 Diagnostic Test (RDT) vs. skin-snip microscopy (SS), and Ov16 RDT vs. 'Oncho' status (skin-

	Ov16 RDT vs. Skin-snip microscopy				Ov16 R	DT vs. 'Oncho	oʻstatus
	SS +ve	SS -ve	SS Total		Oncho +ve	Oncho -ve	Oncho Total
Ov16 +ve	2	17	19		3	16	19
Ov16 -ve	9	66	75		11	64	75
Ov16 Total	11	83	94		14	80	94
	Concordance par						
kappa		20.018				0.0125	
[95% CI]	[?]	0.203 – 0.16	58]			0.190 - 0.21	5]
(P-value)		(0.4292)			(0.4511)		
<i>p</i> ₀		72.3%				71.3%	
p _{pos}		13.3%				18.2%	
P _{neg}		83.5%				82.6%	
McNemar's X^2 statistic		0 188				0 593	
(P-value)		(0.1698)				(0.4414)	
Sensitivity	18.2%					21.4%	
Specificity	79.5%					80.0%	
PPV		10.5%				15.8%	
NPV	88.0%					85.3%	

371 snip and/or nodule palpation).

372 p_0 = Overall proportion of agreement; p_{pos} = Proportion of positive agreement;

373 p_{neg} = Proportion of negative agreement; PPV = Positive predictive value; NPV = Negative

374 predictive value.

375

376 Acceptability of Ov16 RDT, skin-snip microscopy and nodule palpation

- The 94 individuals who participated in all three tests were interviewed after the diagnostics were completed (exit questionnaire, S1 Text). The majority of the participants (71/94 = 75.5%) preferred the Ov16 RDT to skin-snip microscopy for reasons including that the Ov16 RDT procedure was less painful, less invasive and that they could see their results in 30–40 minutes, rather than waiting until the next field visit to learn whether or not they were 'positive':
- 383 *"This test (Ov16 RDT) is better! It is less painful than the one where you (health personnel)*
- 384 *'cut the buttocks' (skin snip)" (Female participant, Abekwai 2).*
- 385 *"I don't normally see the need to participate in the test where you take some skin from my*
- buttocks. A lot of times, you (health personnel) just cut the skin and we don't hear anything
- 387 about our results. I like this new one (Ov16 RDT) as I got to know my results immediately"
- 388 (Male participant, Abekwai 3).
- Despite the majority's preference for Ov16 RDTs, 34% (32/94) remarked that they were 'okay' with skin-snip microscopy and were willing to 'endure' the pain, as long as they were convinced that undergoing the test would improve their health and wellbeing. This proportion of respondents was in agreement with the 37% of the recruited individuals who agreed to be skin-snipped (Table 1).
- "For me, I am okay if you (technician) cut skin on my buttocks (skin snip), as long as it will
 help towards treating me early. The pain is only temporary, good health is what matters"
 (Adult male, Attakrom).

397	However, 20% (19/94) of participants detested the skin-snip method and stated that they
398	would not engage in any future surveys involving this method. The major reasons for this
399	included the painful nature of skin-snipping and its invasiveness. Some participants also
400	argued that they experienced itching, developed a rash or suffered from other allergic
401	reactions after they had been skin-snipped:

- 402 *"For me, I will run away if you (technician) come here again with that your scissors, it is too*
- 403 painful" (Female participant, Johnykrom).
- 404 Regarding the use of nodule palpation, 98% (92/94) of the study participants were 'okay'
- 405 with it, with 18% (17/94) preferring to be examined for nodules by a person of the same
- sex, and 2% (2/94) not being at all comfortable with being palpated for nodules due to
- 407 religious reasons:
- 408 "As for me, I don't like it when the female doctor is touching parts of my body as she will
 409 see my nakedness" (Adult male, Blibor).

410 Usability and acceptability of Ov16 RDT among technicians in the study

411 The study interviewed all nine technicians who performed the Ov16 RDTs and who were 412 also experienced in skin-snip microscopy, with 89% (8/9) preferring the former test over the latter. The reasons for this included that it required less effort and training and met with 413 414 less resistance from the survey participants on the account of being less painful and less 415 invasive. The rapid turnaround time of the Ov16 RDT results (within 30–40 minutes from 416 sampling to results) as opposed to more than 24 hours for skin-snip microscopy further 417 increased the willingness of the community to take part in surveillance activities. The 418 technicians also liked the fact that children were able to participate in the serological 419 survey. Most of the technicians also indicated that they trusted the results from the Ov16

420 RDT as it tends to lend itself to fewer human errors. When prompted on the challenges with 421 the use of the Ov16 RDT, most technicians referred to the fact that being antibody-based, 422 the test could not differentiate between past and current infections. They therefore 423 advocated for both tests; first Ov16 RDT for indication to exposure, followed by 424 confirmation of active infection with skin-snip microscopy when necessary. Nevertheless, all 425 technicians remarked that they would prefer to use Ov16 RDTs in future surveillance 426 activities.

427 Cost analysis for Ov16 RDT and skin-snip microscopy

428 Time considerations. The training of nine technicians for the Ov16 RDT took a maximum of 429 two hours (120 minutes) in contrast to 14 days (6,720 minutes for an 8-hour daily schedule) for the training of five technicians on skin-snip microscopy. The Ov16 RDT took 430 431 approximately 10 minutes to take a sample from each participant (labelling the cassette, 432 selecting, and cleaning a finger, pricking the finger and placing the blood and the assay 433 diluent in the cassette) and 30-40 minutes to get and communicate the results (20 minutes 434 to read the results from the cassette and 10–20 minutes to record such results and convey 435 them to participants). By contrast, skin-snip microscopy took about 30 minutes for sampling 436 from each participant (cleaning left and right iliac crests with alcohol swabs, taking the skin 437 snips with disinfected punches, placing the snips in labelled microtitre plate wells containing 438 incubation medium, recording participant details), 24 hours for the incubation of the snips 439 and about 20 minutes to pipette and observe the incubation medium under a microscope 440 under two magnifications, for a total of 24 hours and 50 minutes (1,490 minutes) to obtain 441 the results. A common concern was that the participants of skin-snip microscopy typically 442 never get to know their results or at best get to know them only during the next field visit,

443 which can take weeks or months. These have cost implications for both Ov16 RDT and skin-

444 snip microscopy tests.

445 Cost considerations. The total cost for the activities targeting 400 participants was estimated 446 at US\$32,156. The cost was apportioned to Ov16 RDT, skin-snip microscopy and shared cost. 447 The costs incurred for Ov16 RDT and skin-snip microscopy test and activities were US\$2,412 448 (7.5%) and US\$22,670 (70.5%), respectively. The shared cost incurred accounted for 22% of the total cost of the study (US\$7,074). Within the total cost, 94.8% (US\$30,484) 449 450 corresponded to fieldwork cost, comprised of transport and lodging (72.0%), supplies, 451 devices and instruments (21.4%), and labour cost (1.4%). Training and reporting costs 452 accounted for 5.1% (US\$1,640) and 0.1% (US\$32) of the total cost, respectively. The total 453 cost per participant of the Ov16 RDT was US\$ 23.72 (US\$6.03 for test-specific costs and 454 US\$17.69 for shared costs); the cost of skin-snip microscopy was US\$74.36 (US\$56.67 for 455 test-specific costs and US\$17.69 for shared costs). The cost per participant of deploying 456 Ov16 RDT and skin-snip microscopy testing based on 400 participants and split by category 457 is presented in Fig 3.

Proportionally reducing costs according to the numbers tested in our study (254 for Ov16 RDT and 94 for skin-snip microscopy) and adjusting for fixed inputs, the total cost of the activity was estimated at US\$24,708 for the 6 communities surveyed, with a net cost per participant of US\$27 for Ov16 RDT and US\$207 for skin-snip microscopy, highlighting the impact of the volume effect [10].

463



464

Fig 3. Cost analysis per Ov16 rapid test (Ov16 RDT) and skin-snip microscopy for 400

466 individuals tested for each diagnostic.

467 **Discussion**

This study aimed to determine the usability, acceptability and cost of the Ov16 RDT for 468 469 onchocerciasis surveillance in endemic communities in the middle belt of Ghana, 470 particularly in the Tain District and Wenchi Municipality where it has been reported that 471 onchocerciasis persists after 27 years of ivermectin MDA [19,20]. The seroprevalence 472 among study participants was 24%, the microfilarial prevalence was 12% and the nodule 473 prevalence was 6%. Sex, age group, occupation and palpable nodule status were 474 significantly associated with Ov16 status, whereas duration of stay in the village, living in 475 proximity to a stream, visiting the stream, frequency of visiting the stream and skin-snip 476 status were not (Table 2). Among the Ov16 seropositives, there was a significantly higher proportion of females, those aged 30 years or older, living near streams, visiting such 477

streams and engaged in farming. However, the proportions of those presenting skin
microfilariae or palpable nodules were significantly lower.

480 Since the study communities have received ivermectin MDA for nearly three decades, 481 those aged \geq 30 years at the time of our study would have been exposed as children to 482 baseline levels of transmission. We have previously reported that the study area was 483 initially mesoendemic, with a baseline microfilarial prevalence of 41% to 48% [20]. This is 484 broadly in agreement with the 33% seroprevalence we found among those 30 years or 485 older. Of the 126 females sampled, more than half (61%) were aged \geq 30 years, whereas of 486 the 116 males sampled, less than half (44%) belonged to this age group; nearly 100% of those 30 years of age or older were farmers (76/77 females and 50/51 males). 487

488 As the blackfly vectors breed in fast-flowing rivers and streams [1], it is perhaps not 489 surprising that those living near or visiting such water bodies were more frequently 490 represented among seropositive individuals, but contrary to expectation the proportion of 491 those visiting streams daily was lower than that of those visiting less often. Farming can be 492 another activity that increases exposure to blackfly bites, and historically, agricultural 493 communities are known to have been highly endemic for onchocerciasis as farms are often 494 situated near rivers that provide water for crops [29]. As blackflies are outdoor and diurnal 495 biters, farmers working outdoors for several hours of the day may have an increased risk of exposure. In the Tombel Health District, Southwest region of Cameroon, and after 15 496 497 years of CDTI, Nyagang et al. [30] reported higher onchocerciasis prevalence in those aged 498 more than 60 years, who were mostly farmers. The greatest prevalence of infection (2.1%) 499 was among farmers [30]. A study in Southwest Ethiopia, also after 15 years of CDTI, reported that individuals aged \geq 35 years had a microfilarial prevalence of 15.7% compared 500

to 1.4% in those aged 15–24-years (no children under 15 were examined), and that approximately 60% of the participants were farmers, of whom 9% were microfilariapositive [31]. The authors stated that adults were engaged in outdoor activities, increasing their exposure to blackfly bites [31].

505 Although Ov16 seroprevalence levels, particularly in the young, have been considered to 506 indicate exposure to infection, knowledge of the parasite stage(s) that elicit IgG4 antibody 507 seroconversion to the Ov16 antigen, as well as of the dynamics of seroconversion and 508 potential seroreversion or antibody decay under transmission interruption remains 509 outstanding. Willen et al. [32,33] reported, using data from Ghana, on the development of an IgG-based immunoassay to quantify antibodies to Simulium damnosum sensu lato 510 511 saliva that, if combined with assays to detect past or current exposure to O. volvulus could 512 help to investigate exposure to blackfly bites and to the parasite.

513 In our study, Ov16, skin-snip and nodule positivity were generally higher among those 514 aged 30 years or older (with the exception of microfilarial prevalence, which was lowest in 515 those \geq 40 years of age). Since only 94/254 (37%) of the participants agreed to be skinsnipped, with complete data on age and sex for 91 of these, our results need to be 516 517 interpreted with caution. Notwithstanding our small sample sizes, 11%, 23% and 4% of the 518 5-9-year olds examined were positive for antibodies against Ov16, microfilaridermia and 519 onchocercomas, respectively (Table 3). As the nodule-positive child was aged 5 and the 520 pre-patent period (from infection to detectable microfilaridermia) of O. volvulus has been 521 estimated to range between 1 and 3 years [34], we can infer that this child became 522 infected when he was 3–4 years of age, underscoring the occurrence of ongoing 523 transmission in the study villages. Although Ov16 seroprevalence by age was generally

higher for females compared to males (with the exception of the 5–9-year age group),
sample sizes were small, leading to wide 95%CIs (Fig 2), precluding us from drawing firm
conclusions about sex- and age-specific exposure patterns.

The low positive agreement between Ov16 and skin-snip positivity is likely explained by the fact that treatment leads to a reduction in skin microfilariae but antibodies to Ov16 may remain for much longer [10], with the levels of Ov16 and skin-snip positivity becoming increasingly disassociated as treatment progresses.

531 The McNemar chi-square statistic showed no association between Ov16 RDT and skin-snip 532 microscopy (or 'Oncho' status when combining skin-snip microscopy and/or nodule 533 palpation), indicating that Ov16 RDT is not an appropriate tool for determination of active 534 infection trends in surveillance activities, for which, in any case, it was not designed. 535 However, given the relatively high level of negative agreement (83%–84%) and NPV (85%– 536 88%), it may be possible to use Ov16 RDT for screening (all ages), subsequently focusing on 537 those Ov16 positive for further testing with skin-snip microscopy and/or skin-snip PCR. 538 According to the RDT manufacturer, the test has 81% sensitivity and 99% specificity [10], 539 but likely due to long-term treatment in the study area, our estimated values were very low (about 20% and 80%, respectively) (Table 4). 540

We acknowledge that the WHO guidelines for stopping MDA and verifying elimination of transmission do not advocate the use of Ov16 serology to detect active infection or its use in all ages, but rather in those under 10 years of age using ELISA, with a seropositivity <0.1% at the upper 95% confidence bound in a sample of 2,000 children being taken as an indication of transmission interruption [35]. Modelling studies have investigated the applicability, to predict EOT outcomes, of this (and less stringent) threshold(s) and age

group(s) under different assumptions of exposure and regulation of parasite abundance
[36], and ongoing studies (some in Ghana) are being conducted to test such thresholds in
the field.

550 We found that conducting Ov16 RDT testing in all ages provided useful information 551 interpretable in the context of the duration of treatment in the area, as done by others in Mali and Tanzania [37,38]. Our results also indicate that the study communities are not yet 552 553 at the point of commencing Stop-MDA surveys despite having received nearly three 554 decades of ivermectin MDA. However, since we did not sample 2,000 children aged less 555 than 10 years, our results are surrounded by considerable uncertainty. Despite this 556 uncertainty, we have documented persistence of O. volvulus infection and associated clinical manifestations in the study area [19,20], and investigated factors influencing 557 558 treatment adherence which could partly explain such persistence [21]. Entomological 559 studies should also be undertaken in the study area to assess infection levels in simuliid 560 population samples.

561 Studies done in other African settings with long-term CDTI (using the Ov16 RDT with whole 562 blood) have reported, in the Ulanga district of Morogoro, Tanzania (an initially hyperendemic area), seroprevalence levels of 14% (27/191) in those aged 6–10 years and 563 564 33% (26/79) in those aged 11–12 after more than 20 years of CDTI [39]. In a formerly 565 highly endemic area in the Mbam and Sanaga river valleys of Cameroon, Siewe Fodjo et al. 566 [40] found an Ov16 seropositivity of 47% (68/145) in Bilomo (Centre Region) and 52% (13/25) in Kelleng (Littoral Region) among children aged 7–10 years after >13 years of 567 568 CDTI. A factor likely involved in the persistence of onchocerciasis in this area is the very high (and perennial) biting rates of the blackfly vectors, as documented in other localities 569

570 of the Mbam and Sanaga river systems, both historically and recently [41,42]. As our study area was originally mesoendemic, and annual biting rates in the region were of the order 571 572 of 3,000–4,000 per person [19], it would be advisable to update entomological studies in 573 the Tain District and Wenchi Municipality of Ghana to better understand the potential 574 contribution of blackfly abundance, species composition and transmission intensity to 575 persistent infection. A study in the Nkoranza North District (see Fig 1) documented highly 576 seasonal transmission, with monthly biting rates of approximately 800 in the peak 577 transmission season and 0–100 in other months of the year [43].

578 In terms of diagnostic test acceptability, most participants preferred the Ov16 RDT to skin-579 snip microscopy and nodule palpation on account of its being less invasive, less painful and 580 more rapidly generating results that the participants could see *in situ*. These attributes of 581 the RDT could be capitalised upon to increase the willingness of the population to 582 participate in surveillance activities. Our findings are consistent with those of Dieve et al. 583 [10] in south-eastern Senegal, who reported a greater willingness of participants to take 584 part in onchocerciasis surveillance activities involving Ov16 RDT. Interestingly, the 585 participation rates in Ov16 RDT (99.7%) and skin-snip microscopy (32.7%) in the Senegal 586 study [10] are very similar to ours in Ghana (100% and 37%, respectively), suggesting that 587 about a third of the population might be willing to participate in skin-snipping surveys. As 588 endemic countries transit the path towards onchocerciasis EOT, it is increasingly important 589 that the surveillance tools used in control and elimination programmes are both effective 590 and acceptable. Residents of meso- and hyperendemic communities have typically had a 591 long history of MDA treatment and are, therefore, increasingly apathetic towards control 592 and surveillance activities, especially because the disease is no longer perceived as a major 593 public health problem in some areas.

594 As mentioned, about a third of the individuals taking part in the 'exit' interviews remarked 595 that although skin-snipping is painful, they would be willing to participate in future 596 parasitological surveys using skin-snip microscopy. This was partly due to the research 597 team members explaining to the participants the need for the test and the potential 598 benefits to their health outcomes. Thus, the influence of the surveillance staff on 599 participation rates should not be underestimated. The National Onchocerciasis Control 600 Programme could leverage this finding to tackle issues of growing apathy in endemic 601 communities.

The Ov16 RDT was also generally preferred among the technicians involved owing to its being relatively simple and easy to use, quick turnaround and potential for increasing community participation in future surveys, in agreement with the study in Senegal [10]. However, the technicians in our study were well aware of the Ov16 RDT limitations concerning its inability to distinguish between past and present exposure/infection.

607 For a total of 400 individuals, the total cost per participant was estimated as US\$24 for 608 Ov16 RDT and US\$74 for skin-snip microscopy, the former being approximately a third of 609 the cost of the latter. The difference in cost between the two tests per individual (US\$50) 610 was mainly driven by differences in transport and lodging, supplies, devices and 611 instruments, labour and training. Regarding training requirements, Ov16 required a 612 relatively short time (approximated 2 hours) to train nine technicians. By contrast, skin-613 snip microscopy training (sample-taking technique and microscopy) took 14 days. Also, 614 supplies, devices and instruments needed for skin-snip microscopy include expensive 615 instruments such as corneoscleral punches, microscopes, microtitre plates, pipettes etc., 616 whereas those for Ov16 RDT principally include the kits from the manufacturer. Although the cost of transport and lodging was considered jointly for the deployment of the two tests and allocated according to the proportion of costs for each specific test and their shared costs, it is important to note that if Ov16 RDT alone were used in typical surveillance, fewer days would likely be necessary, making the Ov16 RDT even less costly. Nevertheless, challenges with Ov16 RDT procurement must be considered when planning surveillance activities.

623 Limitations. Our study has a number of limitations that should be addressed in future work. 624 Firstly, study participants were not randomly sampled and, therefore, study results need to 625 be interpreted with caution as they may not be truly representative of the study 626 communities. Sample sizes to ensure a given power or precision were not calculated before 627 the study; only people who agreed to gather at the focal point in their communities were 628 included in the study (convenience sampling), with only 12% of the population participating 629 overall (Table 1). This likely led to bias. Participants with clinical manifestations seeking to 630 be examined by the research team may also be those with greater levels of infection, 631 leading to overestimation of prevalence levels. Alternatively, individuals who have greater 632 adherence to treatment may also have greater willingness to participate in surveillance 633 activities, with the surveys missing a proportion of those who have higher levels of infection, 634 resulting in underestimation. Secondly, social desirability bias may have influenced the 635 results of the usability and acceptability surveys, as they were based purely on verbal 636 responses. Thirdly, the slides prepared from the incubation medium of the skin snips for 637 detection of O. volvulus microfilariae were not fixed and stained to assess their 638 characteristic morphological features, and no skin-snip PCR was conducted to confirm 639 species-specific identification. Therefore, we cannot totally rule out the presence of other

640 filarial species in the skin snips such as *Mansonella streptocerca* (skin-dwelling 641 microfilariae), or even *M. perstans* (blood-dwelling microfilariae that may be present in the 642 event that snips were not wholly bloodless). Fourthly, we used the Ov16 RDT with whole 643 blood, but collecting dried blood samples that are eluted in the lab and used in the RDT may 644 reach a sensitivity similar to that of the Ov16 ELISA recommended by the WHO [44]. 645 However, this procedure would increase the reading time of the results to 30 minutes-24 646 hours, with the latter recommended for increased accuracy of seroprevalence estimates 647 [44,45]. Finally, as our cost estimates were calculated using specific costs for Ghana, there is 648 a need for similar implementation research in other endemic countries and settings, as 649 exemplified by the very different cost estimates presented for Senegal [10].

650 **Conclusions**

651 This study has demonstrated the usability of the Ov16 RDT to identify ongoing transmission 652 using seroprevalence in children aged 5-9 years in an area with nearly three decades of 653 CDTI, and more generally, exposure patterns in the general population. The test was also 654 more acceptable and feasible than skin-snip microscopy, less costly to implement, and may 655 help overcome the increasing reluctance of endemic communities to participate in 656 onchocerciasis surveillance activities. Regardless of these advantageous features, further 657 R&D efforts are necessary to increase the diagnostic performance of serological tests and 658 improve their ability to distinguish between past and patent infection [46]. Ideally, such 659 tests could be used to screen the population and focus on those seropositive for further 660 parasitological testing, or if it can be ensured that the measured antibody responses are 661 elicited by microfilariae and mirror their dynamics following treatment, to obviate this need 662 altogether.

663 Abbreviations

664 CDTI: Community Directed Treatment with Ivermectin; CI: Confidence interval; DALY: 665 Disability Adjusted Life Year; ELISA: Enzyme-Linked Immunosorbent Assay; EOT: Elimination 666 of Transmission; GBD: Global Burden of Disease; IgG: Immunoglobulin G; IgG4: 667 Immunoglobulin G4; MDA: Mass Drug Administration; NPV: Negative predictive value; NTD: 668 Neglected Tropical Disease; OCP: Onchocerciasis Control Programme in West Africa; PCR: 669 Polymerase Chain Reaction; PES: Post-Elimination Surveillance; PPV: Positive predictive 670 value; PTS: Post-Treatment Surveillance; R&D: Research and Development; REMO: Rapid Epidemiological Mapping of Onchocerciasis; RDT: Rapid Diagnostic Test; SSA: Sub-Saharan 671 672 Africa; UI: Uncertainty interval; WHO: World Health Organization.

673 Supporting information

674 S1 Text. Interviewer guide for participants' and technicians' 'exit' interviews after

675 conducting tests.

676 Authors' contributions

677 Conceptualization: Kenneth Bentum Otabil, María-Gloria Basáñez, Henk D.F.H. Schallig,
 678 Robert Colebunders.

- 679
- 680 Data curation: Kenneth Bentum Otabil, María-Gloria Basáñez.
- 681

Formal analysis: Kenneth Bentum Otabil, María-Gloria Basáñez, Lydia Datsa, Andrews
Agyapong Boakye, Robert Colebunders.

684

Funding acquisition: Kenneth Bentum Otabil, María-Gloria Basáñez, Henk D.F.H. Schallig
 Robert Colebunders.

687

Investigation: Kenneth Bentum Otabil, Ameyaa Elizabeth, Michael Oppong, Prince Mensah,
Richmond Gyasi-Ampofo, Emmanuel John Bart-Plange, Theophilus Nti Babae, Michael
Tawiah Yeboah, Prince Nyarko, Prince Charles Kudzordzi, Anabel Acheampong, Edwina
Twum Blay.

692

693 Methodology: Kenneth Bentum Otabil, María-Gloria Basáñez, Henk D.F.H. Schallig, Robert
 694 Colebunders.

- 695
- 696 **Project administration:** Kenneth Bentum Otabil.

697 698 Resources: Kenneth Bentum Otabil, María-Gloria Basáñez, Henk D.F.H. Schallig, Robert Colebunders. 699 700 701 Supervision: María-Gloria Basáñez, Henk D.F.H. Schallig, Robert Colebunders. 702 703 Visualization: Kenneth Bentum Otabil, María-Gloria Basáñez, Lydia Datsa, Andrews Agyapong Boakye. 704 705 706 Writing – original draft: Kenneth Bentum Otabil, Maria-Gloria Basáñez. 707 708 Writing – review & editing: Kenneth Bentum Otabil, María-Gloria Basáñez, Ameyaa 709 Elizabeth, Michael Oppong, Prince Mensah, Richmond Gyasi-Ampofo, Emmanuel John Bart-710 Plange, Theophilus Nti Babae, Lydia Datsa, Andrews Agyapong Boakye, Michael Tawiah 711 Yeboah, Prince Nyarko, Prince Charles Kudzordzi, Anabel Acheampong, Edwina Twum Blay, 712 Henk D.F.H. Schallig, Robert Colebunders. 713

714 Acknowledgements

We thank all the staff and students of the Department of Biological Science and the Centre for Research in Applied Biology who provided support in one way or another to ensure the successful implementation of this research. We also appreciate the efforts of the directors and staff of the Wenchi Municipal Health Directorate, Nsawkaw District and the Subinso Health Centre for their enormous contributions towards the study. Our appreciation also goes to the chiefs and people of the study communities who partnered with us in this study.

721 Funding

This project was supported by a small grant from the Royal Society of Tropical Medicine and Hygiene, UK awarded to KBO in 2020, and from the United States Agency for International Development (USAID) and UK FCDO from the British people (UK FCDO) through the Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD) and administered by the African Research Network for Neglected Tropical Diseases (ARNTD). MGB acknowledges

727	funding from the MRC Centre for Global Infectious Disease Analysis (MRC GIDA, grant
728	number MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK-
729	funded award is carried out in the frame of the Global Health EDCTP3 Joint Undertaking. RC
730	received funding from Research Foundation Flanders (FWO, grant number G0A0522N).

731 Competing interests

The authors declare that there are no competing interests regarding the publication of thisarticle.

734 **Ethical approval**

This study was approved by the Committee for Human Research and Ethics at the University of Energy and Natural Resources, Sunyani, Ghana (approval number: CHRE/AP/012/021). Written informed consent was obtained from all participants before recruitment. All procedures in this study were in accordance with the ethical standards of the Helsinki Declaration (1964, amended most recently in 2008) of the World Medical Association.

740 Availability of data and materials

All the data are contained in the Tables, Figures, and Supporting information.

742 **References**

743	1.	World Health Organization. Onchocerciasis. 2022. Available from:
744		https://www.who.int/news-room/fact-sheets/detail/onchocerciasis.
745	2.	Institute for Health Metrics and Evaluation (IHME). Findings from the Global Burden
746		of Disease Study 2017. Seattle, WA: IHME, 2018. Available from:
747		https://www.healthdata.org/sites/default/files/files/policy_report/2019/GBD_2017
748		Booklet.pdf.

749 750 751 752 753	3.	GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019, Lancet. 2020;396: 1204–1222. Onchocerciasis—Level 3 cause. Available from: https://www.thelancet.com/pb-assets/Lancet/gbd/summaries/diseases/onchocerciasis.pdf .
754 755 756	4.	Bockarie MJ, Kelly-Hope LA, Rebollo M, Molyneux DH. Preventive chemotherapy as a strategy for elimination of neglected tropical parasitic diseases: endgame challenges. Philos Trans R Soc Lond B Biol Sci. 2013;368: 20120144.
757 758 759 760	5.	Mutono N, Basáñez MG, James A, Stolk WA, Makori A, Kimani TN, et al. Elimination of transmission of onchocerciasis (river blindness) with long-term ivermectin mass drug administration with or without vector control in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2024;12: e771-e782.
761 762 763	6.	World Health Organization. Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030. Available from: <u>https://www.who.int/publications/i/item/9789240010352</u> .
764 765	7.	Lakwo T, Oguttu D, Ukety T, Post R, Bakajika D. Onchocerciasis elimination: progress and challenges. Res Rep Trop Med. 2020;11: 81–95.
766 767 768	8.	Taylor HR, Munoz B, Keyvan-Larijani E, Greene BM. Reliability of detection of microfilariae in skin snips in the diagnosis of onchocerciasis. Am J Trop Med Hyg. 1989;41: 467–471.
769 770 771 772	9.	Bottomley C, Isham V, Vivas-Martínez S, Kuesel AC, Attah SK, Opoku NO, et al. Modelling Neglected Tropical Diseases diagnostics: the sensitivity of skin snips for <i>Onchocerca volvulus</i> in near elimination and surveillance settings. Parasit Vectors. 2016;9: 343.
773 774 775	10	. Dieye Y, Storey HL, Barrett KL, Gerth-Guyette E, Di Giorgio L, Golden A, et al. Feasibility of utilizing the SD BIOLINE Onchocerciasis IgG4 rapid test in onchocerciasis surveillance in Senegal. PLoS Negl Trop Dis. 2017;11: e0005884.
776 777 778 779 780 781	11	Abong RA, Amambo GN, Chounna Ndongmo PW, Njouendou AJ, Ritter M, Beng AA, et al. Differential susceptibility of <i>Onchocerca volvulus</i> microfilaria to ivermectin in two areas of contrasting history of mass drug administration in Cameroon: relevance of microscopy and molecular techniques for the monitoring of skin microfilarial repopulation within six months of direct observed treatment. BMC Infect Dis. 2020;20: 726.
782 783 784	12	. Lobos E, Weiss N, Karam M, Taylor HR, Ottesen EA, Nutman TB. An immunogenic <i>Onchocerca volvulus</i> antigen: a specific and early marker of infection. Science. 1991;251: 1603-1605.
785 786 787 788 789	13	Cama VA, McDonald C, Arcury-Quandt A, Eberhard M, Jenks MH, Smith J, et al. Evaluation of an OV-16 IgG4 Enzyme-Linked Immunosorbent Assay in humans and its application to determine the dynamics of antibody responses in a non-human primate model of <i>Onchocerca volvulus</i> infection. Am J Trop Med Hyg. 2018;99: 1041– 1048.

790	14. Lont YL, Coffeng LE, de Vlas SJ, Golden A, de Los Santos T, Domingo GJ, et al.
791	Modelling anti-Ov16 IgG4 antibody prevalence as an indicator for evaluation and
792	decision making in onchocerciasis elimination programmes. PLoS Negl Trop Dis.
793	2017;11: e0005314.
794 795 796	15. Golden A, Stevens EJ, Yokobe L, Faulx D, Kalnoky M, Peck R, et al. A recombinant positive control for serology diagnostic tests supporting elimination of <i>Onchocerca volvulus</i> . PLoS Negl Trop Dis. 2016;10: e0004292.
797 798	16. Vlaminck J, Fischer PU, Weil GJ. Diagnostic tools for onchocerciasis elimination programs. Trends Parasitol. 2015;31: 571–582.
799	17. Biritwum NK, de Souza DK, Asiedu O, Marfo B, Amazigo UV, Gyapong JO.
800	Onchocerciasis control in Ghana (1974-2016). Parasit Vectors. 2021;14: 3.
801 802 803 804	18. Ghana Health Service. Ghana NTD Master Plan 2016–2020. Expanded Special Project for Elimination of Neglected Tropical Diseases. 2020. Available from: <u>https://espen.afro.who.int/system/files/content/resources/GHANA_NTD_Master_Plan_2016_2020.pdf</u> .
805	19. Otabil KB, Basáñez MG, Ankrah B, Opoku SA, Kyei DO, Hagan R, et al. Persistence of
806	onchocerciasis and associated dermatologic and ophthalmic pathologies after
807	272years of ivermectin mass drug administration in the middle belt of Ghana. Trop
808	Med Int Health. 2023;28: 844–854.
809	20. Otabil KB, Ankrah B, Bart-Plange EJ, Donkoh ES, Avarikame FA, Ofori-Appiah FO, et al.
810	Prevalence of epilepsy in the onchocerciasis endemic middle belt of Ghana after 27
811	years of mass drug administration with ivermectin. Infect Dis Poverty. 2023;12: 75.
812	21. Otabil KB, Basáñez MG, Ankrah B, Bart-Plange EJ, Babae TN, Kudzordzi PC, et al. Non-
813	adherence to ivermectin in onchocerciasis-endemic communities with persistent
814	infection in the Bono Region of Ghana: a mixed methods study. BMC Infect Dis.
815	2023;23: 805.
816	22. Kura K, Milton P, Hamley JID, Walker M, Bakajika DK, Kanza EM, et al. Can mass drug
817	administration of moxidectin accelerate onchocerciasis elimination in Africa? Philos
818	Trans R Soc Lond B Biol Sci. 2023;378: 20220277.
819	23. Hutubessy R, Chisholm D, Tan-Torres Edejer T. Generalized cost-effectiveness
820	analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc.
821	2003;1: 8.
822 823	24. Bland M. An Introduction to Medical Statistics. Oxford: Oxford University Press; 1991.
824 825	25. Cicchetti DV, Feinstein AR. High agreement but low kappa: II. resolving the paradoxes. J Clin Epidemiol. 1990;43: 551–558.
826	26. Hazra A, Gogtay N. Biostatistics Series Module 7: the statistics of diagnostic tests.
827	Indian J Dermatol. 2017;62: 18–24.
828 829	27. Brown LD, Cai TT, DasGupta A. Interval estimation for a binomial proportion. Stat Sci. 2001;16: 101–117.

830 831 832 833	28	World Health Organization & African Programme for Onchocerciasis Control. Guidelines for revising ivermectin treatment boundaries within the context of onchocerciasis elimination. African Programme for Onchocerciasis Control. 2015. Available from: <u>https://apps.who.int/iris/handle/10665/343029</u> .
834 835 836	29.	. Eneanya OA, Koudou BG, Aboulaye M, Elvis AA, Souleymane Y, Kouakou MM, et al. Progress towards onchocerciasis elimination in Côte d'Ivoire: a geospatial modelling study. PLoS Negl Trop Dis. 2021;15: e0009091.
837 838 839 840	30.	Nyagang SM, Cumber SN, Cho JF, Keka EI, Nkfusai CN, Wepngong E, et al. Prevalence of onchocerciasis, attitudes and practices and the treatment coverage after 15 years of mass drug administration with ivermectin in the Tombel Health District, Cameroon. Pan Afr Med J. 2020;35: 107.
841 842 843 844	31	Kifle B, Woldemichael K, Nigatu M. Prevalence of onchocerciasis and associated factors among adults aged ≥ 15 years in Semen Bench District, Bench Maji Zone, Southwest Ethiopia: community based cross-sectional study. Adv Publ Health. 2019;2019: 7276230.
845 846 847 848	32.	. Willen L, Basáñez MG, Dvorak V, Veriegh FBD, Aboagye FT, Idun B, et al. Human immune response against salivary antigens of <i>Simulium damnosum</i> s.l.: a new epidemiological marker for exposure to blackfly bites in onchocerciasis endemic areas. PLoS Negl Trop Dis. 2021;15: e0009512.
849 850 851 852	33.	Willen L, Milton P, Hamley JID, Walker M, Osei-Atweneboana MY, Volf P, et al. Demographic patterns of human antibody levels to <i>Simulium damnosum</i> s.l. saliva in onchocerciasis-endemic areas: an indicator of exposure to vector bites. PLoS Negl Trop Dis. 2022;16: e0010108.
853 854	34.	Prost A. [Latency period in onchocerciasis]. Bull World Health Organ. 1980;58: 923– 925 (article in French).
855 856 857	35.	World Health Organization. Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis. Criteria and procedures. 2016. Available from: <u>https://www.who.int/publications/i/item/9789241510011</u> .
858 859 860 861	36.	Hamley JID, Walker M, Coffeng LE, Milton P, de Vlas SJ, Stolk WA, et al. Structural uncertainty in onchocerciasis transmission models influences the estimation of elimination thresholds and selection of age groups for seromonitoring. J Infect Dis. 2020;221(Suppl 5): S510–S518.
862 863 864	37.	. Dolo H, Coulibaly YI, Sow M, Dembélé M, Doumbia SS, Coulibaly SY, et al. Serological evaluation of onchocerciasis and lymphatic filariasis elimination in the Bakoye and Falémé Foci, Mali. Clin Infect Dis. 2021;72: 1585–1593.
865 866 867	38.	. Paulin HN, Nshala A, Kalinga A, Mwingira U, Wiegand R, Cama V, et al. Evaluation of onchocerciasis transmission in Tanzania: preliminary rapid field results in the Tukuyu focus, 2015. Am J Trop Med Hyg. 2017;97: 673–676.
868 869 870 871 872	39.	Mshana MI, Silvestri V, Mushi V, Bonaventura WM, Tarimo D, Ngasala B, et al. Burden and factors associated with onchocerciasis transmission among school-aged children after more than 20 years of Community Directed Treatment with Ivermectin in Ulanga district, Tanzania: a school-based cross-sectional study. PLoS Glob Public Health. 2023;3: e0001919.

873 874 875 876	40.	Siewe Fodjo JN, Tatah G, Tabah EN, Ngarka L, Nfor LN, Chokote SE, et al. Epidemiology of onchocerciasis-associated epilepsy in the Mbam and Sanaga river valleys of Cameroon: impact of more than 13 years of ivermectin. Infect Dis Poverty. 2018;7: 114.
877 878 879	41.	Barbazan P, Escaffre H, Mbentengam R, Boussinesq M. [Entomologic study on the transmission of onchocerciasis in a forest-savanna transition area of Cameroon]. Bull Soc Pathol Exot. 1998;91: 178–182 (article in French).
880 881 882 883	42.	Siewe Fodjo JN, Vieri MK, Ngarka L, Njamnshi WY, Nfor LN, Mengnjo MK, et al. 'Slash and clear' vector control for onchocerciasis elimination and epilepsy prevention: a protocol of a cluster randomised trial in Cameroonian villages. BMJ Open. 2021;11: e050341.
884 885 886	43.	. Otabil KB, Gyasi SF, Awuah E, Obeng-Ofori D, Tenkorang SB, Kessie JA, et al. Biting rates and relative abundance of <i>Simulium</i> flies under different climatic conditions in an onchocerciasis endemic community in Ghana. Parasit Vectors. 2020;13: 229.
887 888 889 890	44.	Nana-Djeunga HC, Sicard CM, Mogoung-Wafo AE, Chesnais CB, Deléglise H, Touka- Nounkeu R, et al. Changes in onchocerciasis Ov16 lgG4 rapid diagnostic test results over one-month follow-up: lessons for reading timeframe and decision-making. Am J Trop Med Hyg. 2022;107: 658–661.
891 892 893 894	45.	Peck RB, Golden AL. Assay of dried blood spots using the SD BIOLINE Onchocerciasis IgG4 Rapid Test. Seattle, WA USA: PATH; 2019. Available from: <u>https://www.path.org/our-impact/resources/assay-dried-blood-spots-using-sd-</u> <u>bioline-onchocerciasis-igg4-rapid-test/</u> .
895 896 897	46.	Bennuru S, Oduro-Boateng G, Osigwe C, Del Valle P, Golden A, Ogawa GM, et al. Integrating multiple biomarkers to increase sensitivity for the detection of <i>Onchocerca volvulus</i> infection. J Infect Dis. 2020;221: 1805–1815.